17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia | Journal for ImmunoTherapy of Cancer | Full Text issued 2019 https://t.co/yziwIO3o7Y
Obinutuzumab perhaps more successful in 17p https://t.co/yziwIO3o7Y
Rituximab responsible for relapse? Published 2019 #CLL https://t.co/yziwIO3o7Y
RT @sitcancer: #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mW…
RT @sitcancer: #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mW…
#JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mWycp4lb https://t.co/s21xGTJQfE
RT @GICC_Tours: In CLL, 17p/TP53 deletion influences rituximab pharmacokinetics - A collaboration of our @PATCH_research team (D. Ternant &…
In CLL, 17p/TP53 deletion influences rituximab pharmacokinetics - A collaboration of our @PATCH_research team (D. Ternant & G. Paintaud) with @InsermU1227 et @CHRU_Brest in @sitcancer cc @UnivTours @FacmedTours https://t.co/qBIMfjC3nX https://t.co/VBr
RT @sitcancer: #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mW…
RT @sitcancer: #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mW…
#JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mWycp4lb https://t.co/azvKc5RKQi
#JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mWycp4lb https://t.co/tBbPrM7WjC
RT @sitcancer: New #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/…
RT @DrRaulCordoba: Should we give higher doses of #Rituximab in del17p #CLL patients? #CLLsm #leusm 🤔 https://t.co/sVrz7JB0kO
RT @sitcancer: New #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/…
RT @DrRaulCordoba: Should we give higher doses of #Rituximab in del17p #CLL patients? #CLLsm #leusm 🤔 https://t.co/sVrz7JB0kO
Should we give higher doses of #Rituximab in del17p #CLL patients? #CLLsm #leusm 🤔
New #JITC Short Report: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia https://t.co/Z6mWycp4lb https://t.co/nAiiSUTu1A